Adverum Biotechnologies, Inc.
ADVM
$3.08
$0.051.65%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.62% | 22.32% | -123.08% | 11.03% | -12.34% |
| Total Depreciation and Amortization | -21.67% | -15.68% | -8.99% | -6.90% | -4.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -28.39% | -85.14% | 649.80% | -61.04% | 42.74% |
| Change in Net Operating Assets | 3,383.72% | -97.59% | 322.52% | 6.61% | 179.32% |
| Cash from Operations | 9.36% | -51.41% | -33.73% | -6.45% | 14.63% |
| Capital Expenditure | 45.45% | -260.66% | 72.40% | -1,281.25% | 82.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1.66% | 863.08% | 68.55% | -467.94% | 89.47% |
| Cash from Investing | 1.99% | 846.72% | 68.61% | -473.53% | 89.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | 100.00% | -100.10% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 41.32% | 64.31% | 6.59% | -54.66% | -129.87% |